Publications
Detailed Information
Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yeni | - |
dc.contributor.author | Shin, Min-Sup | - |
dc.contributor.author | Kim, Jae-Won | - |
dc.contributor.author | Yoo, Hee-Jung | - |
dc.contributor.author | Cho, Soo-Churl | - |
dc.contributor.author | Kim, Boong-Nyun | - |
dc.date.accessioned | 2010-04-19T01:40:21Z | - |
dc.date.available | 2010-04-19T01:40:21Z | - |
dc.date.issued | 2009-02-20 | - |
dc.identifier.citation | Hum Psychopharmacol Clin Exp 2009 ;24(2):95-102. | en |
dc.identifier.issn | 1099-1077 (Electronic) | - |
dc.identifier.issn | 0885-6222 (Print) | - |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19226534 | - |
dc.identifier.uri | https://hdl.handle.net/10371/63327 | - |
dc.description.abstract | OBJECTIVES: This study evaluated neurocognitive changes after switching from immediate release forms of methylphenidate (MPH-IR) to osmotic release oral system methylphenidate (OROS-MPH). METHODS: 102 children with attention-deficit/hyperactivity disorder (ADHD) participated in an open label, 28 day trial, performing neurocognitive test at baseline and at 28 days after the switch from MPH-IR to OROS-MPH. RESULTS: There were significant improvements in the commission error and the reaction time of both visual and auditory continuous performance tests (CPTs) at 28 days after switching from MPH-IR to OROS-MPH. A positive correlation was observed between the improvement in parent/caregiver-rated IOWA Conners total score (Delta IOWA) and the reduction in commission error (r = 0.3, p = 0.001) and reduction in reaction time variability (r = 0.3, p = 0.006) of visual CPT. In a linear regression model, the change in parent/caregiver-rated IOWA Conners scale total scores were significant predictors of change in commission error (beta = 0.3, p = 0.005, CI = 0.4-2.3, adjusted R(2) = 0.12) and RT variability (beta = 0.3, p = 0.004, CI = 0.5-2.4, adjusted R(2) = 0.09) of visual CPT. CONCLUSIONS: These data suggest that MPH-IR may be successfully switched to OROS-MPH treatment with associated improvements in neurocognitive performance. Large-scale controlled trials are needed to replicate these findings. | en |
dc.language.iso | en | en |
dc.publisher | Wiley-Blackwell | en |
dc.subject | Administration, Oral | en |
dc.subject | Attention Deficit Disorder with Hyperactivity/*drug | en |
dc.subject | therapy/physiopathology | en |
dc.subject | Central Nervous System Stimulants/*administration & dosage | en |
dc.subject | Child | en |
dc.subject | Cognition Disorders/*drug therapy/etiology | en |
dc.subject | Delayed-Action Preparations | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Linear Models | en |
dc.subject | Male | en |
dc.subject | Methylphenidate/*administration & dosage | en |
dc.subject | Neuropsychological Tests | en |
dc.subject | Reaction Time/drug effects | en |
dc.title | Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 김예니 | - |
dc.contributor.AlternativeAuthor | 신민섭 | - |
dc.contributor.AlternativeAuthor | 김재원 | - |
dc.contributor.AlternativeAuthor | 유희정 | - |
dc.contributor.AlternativeAuthor | 조수철 | - |
dc.contributor.AlternativeAuthor | 김붕년 | - |
dc.identifier.doi | 10.1002/hup.1010 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.